RENAL CELL CARCINOMA IN TRANSPLANT RECIPIENTS WITH ACQUIRED CYSTIC

CJASN ePress. Published on April 25, 2007 as doi: 10.2215/CJN.03661106

Renal Cell Carcinoma in Transplant Recipients with Acquired Cystic Kidney Disease Anke Schwarz, Serap Vatandaslar, Saskia Merkel, and Hermann Haller Department of Nephrology, Hannover Medical School, Hannover, Germany Acquired cystic kidney disease (ACKD) is a widely known renal cell carcinoma risk factor. An ultrasound screening of the native kidneys in all renal transplant patients of a renal outpatient clinic who received a transplant between 1970 and 1998 and presented between 1997 and 2003 (n ⴝ 916) was initiated prospectively. A total of 561 patients were screened. A total of 129 (23%) patients had ACKD; 46 (8.2%) patients had complex renal cysts (Bosniak classification, category IIF to III); and eight (1.5%) patients had newly diagnosed renal cell carcinoma, seven of which were associated with ACKD (category IV). One patient had renal cell carcinoma in the transplanted kidney. Together with 19 patients of the cohort with formerly diagnosed renal cell carcinoma (18 of them associated with ACKD), the prevalence of renal cell carcinoma among all patients was 4.8%; among the patients with ACKD, it was 19.4% (without ACKD 0.5%; P ⴝ 0.0001); and among the patients with complex renal cysts (category IIF to III), it was 54.4%. The patients with ACKD were older (54 ⴞ 13 versus 51 ⴞ 14 yr; P ⴝ 0.048), more often male (65 versus 54%; P ⴝ 0.03), more often had heart disease (44 versus 29%; P ⴝ 0.001), had larger kidneys (6.9 and 6.8 cm versus 6.0 and 5.9 cm; P < 0.001), and had more calcifications (29 versus 15%; P ⴝ 0.002). Renal cell carcinoma was bilateral in 26% of cases. Tumor histology was clear cell carcinoma in 58% and papillary carcinoma in 42% of cases; one patient had both. Only one patient had a lung metastasis, and no patient died. It is concluded that renal cell carcinoma occurs often after renal transplantation and that especially patients with ACKD should routinely be screened. Because ACKD after renal transplantation seems to be less frequent (23%) than during dialysis treatment (30 to 90%), renal transplantation may inhibit renal cell carcinoma. Clin J Am Soc Nephrol ●●: ●●●-●●●, ●●●●. doi: 10.2215/CJN.03661106

R

educed renal function and the development of renal cysts is widely known association (1– 4). Acquired cystic kidney disease (ACKD) has been described as cyst formation in a noncystic failing kidney (2). Cysts originate in dilated renal tubules and increase with the duration of renal insufficiency, even after reaching end-stage renal failure (2,3,5,6). Tissue loss that is associated with renal insufficiency may promote hyperplasia of tubular epithelial cells, resulting in cyst formation (2,7), and atypical epithelial proliferation in the cysts may represent the precursor lesion of renal cell carcinoma (8,9). We performed a prospective study in transplant recipients to determine the prevalence of renal cell carcinoma and ACKD and their relationship and the development of complex renal cysts.

Materials and Methods We studied all patients who received a transplant between 1970 and 1998 and had at least one patient visit to our outpatient clinic between 1997 and 2003. We wrote to the patients and to their nephrologists and

Received November 2, 2006. Accepted March 7, 2007. Published online ahead of print. Publication date available at www.cjasn.org. A.S. and S.V. contributed equally to this work. Address correspondence to: Prof. Anke Schwarz, Department of Nephrology, Hannover Medical School, Carl Neuberg Strasse 1, D-30625 Hannover, Germany. Phone: ⫹49-5115326319; Fax: ⫹49-511-552366; E-mail: [email protected] Copyright © ●●●● by the American Society of Nephrology

asked the patients to have an ultrasound of the native kidneys done by their nephrologist. Cystic lesions of the kidney were defined according to the Bosniak Renal Cyst Classification System (10,11). That means that cysts that are defined as Bosniak category I and II are benign simple cysts with a hairline thin wall that may contain a few hairline thin septa and fine calcifications but no solid components and no enhancement after contrast media; high-attenuation renal lesions ⬍3 cm may be included. Cysts that are defined as Bosniak category IIF are cysts that may contain multiple hairline thin septa or minimal smooth thickening of their wall or septa or may contain calcifications or intrarenal nonenhancing high-attenuation renal masses ⬎3 cm (moderately complex cystic lesions). Cysts that are defined as Bosniak category III show “indeterminate” cystic masses with thickened walls and septa with enhancement after contrast media. Cysts that are defined as Bosniak category IV are clearly malignant cystic masses. ACKD was defined as more than three cysts in both kidneys. Complex cystic lesions were defined as those with irregularly thickened cyst walls, hyperdense or nonhomogenic cyst content and/or pronounced intrarenal calcifications, and/or positive enhancement after intravenous application of contrast media (Bosniak category IIF to III [10 –13]). Ultrasound was followed by computed tomography (CT) scan or magnetic resonance imaging when a moderately complex cystic lesion of the kidney was found (Bosniak category IIF) or in case of suspicion of renal cell carcinoma (category III or IV; Table 1, Figure 1). Aside from renal cell carcinoma, complex renal cysts, and ACKD, we looked for clinical parameters as possible risk factors or associated conditions for the development of ACKD. We focused on age; gender; time on dialysis treatment; time after renal transplantation; number of transplantations; the kind and the number of immunosuppressive drugs; the kind of ISSN: 1555-9041/●●●●–0001

2

Clinical Journal of the American Society of Nephrology

Clin J Am Soc Nephrol ●●: ●●●-●●●, ●●●●

Table 1. Recommendation for patient screening of the native kidneys in renal transplant patients according to the Bosniak renal cyst classification (11)a 1. All patients should have an ultrasound screening of their native kidneys once a year irrespective of ACKD. 2. Patients with ACKD and cysts according to Bosniak category I and II (benign simple cysts): Ultrasound screening twice a year; CT scan in the case of progressive lesions. 3. Patients with ACKD and cysts according to Bosniak category IIF (moderately complex cystic lesions): Ultrasound screening four times a year; CT or MRI scan once a year; nephrectomy in the case of progressive lesions, even if not reaching category III or IV. 4. Patients with ACKD and cysts according to Bosniak category III (⬙indeterminate⬙ cystic masses) and IV (clearly malignant cystic masses): Nephrectomy. 5. Patients with ACKD in general: Generous indication for nephrectomy even in the lower categories, if progression occurs, because the original sense of the Bosniak classification (to preserve renal tissue by exact preoperative diagnosis) has lost its importance in patients with end-stage renal failure. This is true especially for cystic lesions of category IIF. a

ACKD, acquired cystic kidney disease; CT, computed tomography; MRI, magnetic resonance imaging.

underlying kidney disease; accompanying diseases such as hypertension, diabetes, coronary heart disease, and/or heart failure; presence of renal calcifications; and renal size (longitudinal diameter). Patients with ACKD (Bosniak category I to II), with complex renal cysts in the course of ACKD (category IIF to III), and with ACKD-associated renal cell carcinoma (category IV) were compared with the group without these conditions (Table 2). For statistical evaluation, the SPSS statistical package (Version 11.0.1; SPSS, Chicago, IL) was used for all analyses. Unpaired t test with Bonferroni adjustment for multiple comparisons or ␹2 analysis was used as appropriate to assess the differences between groups. Odds ratios for the primary end points (prevalence of ACKD, complicated renal cysts, and ACKD-associated renal carcinoma) were calculated from 2⫻2 contingency tables (Fisher exact test). For multivariate analysis, the effect of multiple parameters on the primary end point was analyzed in all cases with stepwise forward logistic regression analysis (variables with P ⱖ 0.1 were removed from the analysis, and variables with P ⱕ 0.05 were retained). All results are presented as means ⫾ SD. P ⬍ 0.05 was considered significant.

Results A total of 999 patients received a transplant between 1970 and 1998 and had at least one patient visit to our renal outpatient clinic between 1997 and 2003. Nine patients had died, and 74 underwent bilateral nephrectomy; therefore, 916 patients were included to the ultrasound study. In correspondence to our letters to patients and their nephrologists with the request of performing an ultrasound of the native kidneys, 561 patients followed this invitation (61.2% of the included patients). Patients with polycystic kidney disease (PKD; n ⫽ 52) were excluded from the evaluation of kidney size and calcification; therefore, for these parameters, 509 patients were evaluated. Mean age of the 561 patients was 51.7 ⫾ 13.4 yr. There were more men (n ⫽ 319) than women (n ⫽ 242) in the group (57 versus 43%; P ⫽ 0.001). The underlying renal disease of the 561 patients was biopsy-confirmed glomerulonephritis (21.9%), not clarified renal disease including cases with suspected but not biopsy-confirmed glomerular disease (32.1%), PKD (9.3%), interstitial nephritis (10%), renal dysplasia or reflux (8.2%), diabetes (5.9%), vascular renal disease (4.6%), hereditary renal

disease (4.3%), analgesic nephropathy (2.1%), and various remaining conditions (3.6%). Fourteen percent of the patients had received more than one transplant (11.1% second, 2.3% third, and 0.5% fourth kidney). The reason for unilateral or bilateral nephrectomy in 164 patients had been infection (23.2%), complications of stone kidneys (3.7%) or PKD (25%), different kinds of tumor (15.9%), tumor prophylaxis in analgesic nephropathy (6.1%), hydronephrosis (6.7%), reflux (6.1%), intractable high BP (3.7%), not clarified reason (3%), trauma (0.6%), and miscellaneous reasons (6.1%). A total of 129 (23%) patients had ACKD (including 18 patients who had already undergone nephrectomy because of ACKD-associated renal cell carcinoma or suspicion of it). Complex cysts were present in 46 of the patients with ACKD (Bosniak category IIF, n ⫽ 18; category III, n ⫽ 4; category IV, n ⫽ 6; an additional 18 patients with Bosniak categories III and IV had already undergone nephrectomy [8.2% of all evaluated patients and 35.7% of the patients with ACKD]). Renal cell carcinoma was newly suspected in 11 patients, 10 of whom had complex cysts; nephrectomy confirmed renal carcinoma in eight of these patients. Thus, renal cell carcinoma was newly diagnosed and confirmed by nephrectomy in eight patients (1.5% of all patients), 7 of which were associated with complex cysts and ACKD (6.3% of the patients with ACKD and 25% of the patients with complex cysts; Figure 1). In addition, one renal cell carcinoma was found in the renal transplant itself, which had no cysts. In the patient cohort, 19 patients had undergone unilateral (n ⫽ 7) or bilateral (n ⫽ 12) nephrectomy because of renal cell carcinoma; 18 of these 19 patients also had ACKD. Thus, with these 19 patients with known and eight patients with newly diagnosed renal cell carcinoma, we had a group of 27 patients with renal cell carcinoma of the native kidneys (4.8%) and one patient with newly diagnosed renal cell carcinoma of the renal transplant. In 25 (92.6%) of the 27 tumor patients, renal cell carcinoma was found together with ACKD, in one case together with PKD, and in one case with a shrunken kidney. Previously diagnosed (n ⫽ 18) and newly diagnosed (n ⫽ 7) patients with


Figure 1. Complex cystic lesion of the left shrunken kidney. (A) Computed tomography: Thickened wall with irregular contour and hyperdense cyst content. (B) The same cyst after nephrectomy. (C) The opened cyst reveals renal cell carcinoma.

ACKD-based renal carcinoma taken together, 25 (19.4%) of 129 patients with ACKD and 25 (54.4%) of 46 with complex cysts had renal cell carcinoma. That means that renal cell carcinoma was significantly more frequent in patients with ACKD than in those without (19.4 versus 0.46%; P ⫽ 0.0001). In 19 carcinomas of 15 patients (58%), the tumor histology was a clear cell carcinoma, and in 14 carcinomas of 12 patients (42%), the tumor histology was a papillary carcinoma (one

Acquired Cystic Kidney Disease and Renal Transplantation

3

patient with clear cell plus papillary carcinoma; Figure 2). The tumors often were multifocal or even multiple. In seven (26%) of 27 patients, a bilateral tumor was found (four cases with clear cell and four cases with papillary carcinoma; one patient had a papillary carcinoma of the right side and a clear cell plus a papillary carcinoma of the left side). The tumor classification was pT1 in 22 cases of 17 patients (11 with clear cell and 11 with papillary carcinoma), pT2 in seven cases of seven patients (four with clear cell and three with papillary carcinoma), and pT3 in five cases of four patients (four with clear cell and one with papillary carcinoma). The tumor was graded G1 in six cases of five patients (five with clear cell and one with papillary carcinoma), G2 in 28 cases of 24 patients (14 with clear cell and 14 with papillary carcinoma), and there was no case with G3. There was no lymph node involvement in any of the patients. One patient with clear cell carcinoma had a lung metastasis, which was successfully treated by operative resection. The tumor of the transplant was classified pT1, N0, M0, and G1 to 2. Bilateral nephrectomy because of suspected tumor was done in 14 of 27 patients; however, the tumor was bilaterally confirmed in only seven cases. The tumor of the renal transplant was successfully treated by pole resection. Unilateral nephrectomy of a complex cystic lesion and suspected tumor without confirmation was done in five cases. The comparison of the patients with ACKD (n ⫽ 129) including those with complex cysts (n ⫽ 46) and ACKD-associated renal cell carcinoma (n ⫽ 25) with the others without ACKD (n ⫽ 432) showed that they were significantly older and more often male, they had significantly more often accompanying cardiac diseases and less often diabetes, and their kidneys were larger and more often had calcifications (Table 2). The comparison of the patients with complex renal cysts (Bosniak category IIF to IV; n ⫽ 46) including those with ACKD-associated renal cell carcinoma (n ⫽ 25) with those without ACKD (n ⫽ 432) showed that they tended to be older (NS), they were significantly more often male, and had significantly more accompanying cardiac diseases and renal calcifications (Table 2). Basic immunosuppression in patients with complex cysts without confirmed malignancy (Bosniak category IIF and III; n ⫽ 21) compared with those with confirmed malignancy (Bosniak category IV; n ⫽ 25) was not significantly different: Use of prednisolone in 21 of 21 versus 22 of 25 patients (100 versus 88%; NS); use of cyclosporine in 18 of 21 versus 21 of 25 patients (86 versus 84%; NS); use of tacrolimus in two of 21 versus two of 25 patients (10 versus 8%; NS); use of mycophenolate mofetil in six of 21 versus eight of 25 patients (29 versus 32%; NS); use of azathioprine in five of 21 versus five of 25 patients (21 versus 20%; NS); and use of triple therapy in nine of 21 versus nine of 25 patients (43 versus 36%; NS). The comparison of the patients with confirmed ACKD-associated renal cell carcinoma (Bosniak category IV; n ⫽ 25) with those without ACKD (n ⫽ 432) showed again that these patients tended to be older and more often male; however, because of the small number of patients, the differences were not statistically significant (Table 2). They had significantly more accompanying cardiac diseases (Table 2). The time after trans-

4



Table 2. Clinical parameters in patients with ACKD, patients with ACKD and complex cysts, and those with ACKD-associated carcinoma compared with the others who served as control subjectsa Patients (n ⫽ 561)

Age (yr) Gender (% male) Time after transplantation (mo) Time passed at dialysis (mo) Time of dialysis and transplant (mo) No. of transplantations (%) 1 2 3 4 Immunosuppressive therapy (%) triple therapy cyclosporine Underlying renal disease (%) not clarified glomerulonephritis interstitial nephritis dysplasia/reflux analgesic nephropathy PKD hereditary renal disease renal vascular disease diabetes various High BP (%) Diabetes (%) Associated cardiac diseases (%)

Renal calcifications (%) one side both sides Kidney length (cm) right left

ACKD (Including ACKD and Complex Cysts ACKD-Associated Controls (Other Complex Cysts and (Including ACKD-Associated Renal Cell Patients without P P ACKD-Associated Renal Cell Carcinoma) Carcinoma ACKD) (Univariate) (Multivariate) Renal Cell Carcinoma) (n ⫽ 46) (n ⫽ 25) (n ⫽ 432) (n ⫽ 129) 53.9 ⫾ 13.5 73.9c

53.7 ⫾ 13.1 72.0

105.4 ⫾ 62.6 62.0 ⫾ 47.3 167.4 ⫾ 70.4

94.4 ⫾ 72.7 49.0 ⫾ 36.7 143.4 ⫾ 74.6

74.4 ⫾ 72.8 50.6 ⫾ 41.6 125.0 ⫾ 80.3b

86 12.4 1.6

87.0 8.7 4.3

84.0 12.0 4.0

86.1 10.6 2.5 0.7

NS NS NS NS

41.9 76.7

41.3 84.8

36.0 84.0

34.5 80.6

NS NS NS

38 25.6 9.3 5.4 2.3 0 4.7 3.9 7 3.9 97.7 7.8b 44.2b

32.6 37.0 10.9 2.2 0 0 2.2 2.2 8.7 4.3 95.7 8.7 47.8c

32 32 16 0 0 0 4.0 4.0 8.0 4.0 96.0 16.0 48d

30.3 20.8 10.2 6.5 2.1 12 4.2 4.9 5.6 3.5 97.2 14.1 29.2

(n ⫽ 114)b 12.3 16.7

(n ⫽ 31)c 22.6 12.9

(n ⫽ 10) 0 10

(n ⫽ 380) 5.0 10.3

(n ⫽ 107) 6.9 ⫾ 2.1b (n ⫽ 109) 6.8 ⫾ 2.3b

(n ⫽ 27) 6.45 ⫾ 1.43 (n ⫽ 29) 6.36 ⫾ 1.55

(n ⫽ 8) 6.28 ⫾ 1.43 (n ⫽ 9) 6.30 ⫾ 1.82

(n ⫽ 366) 5.99 ⫾ 1.50 (n ⫽ 366) 5.87 ⫾ 1.58

53.8 ⫾ 12.8b 65.1b

b

51.1 ⫾ 13.5 54.4 108.1 ⫾ 60.1 54.6 ⫾ 47.8 162.7 ⫾ 69.8

0.048b 0.031b 0.011c 0.007b NS 0.01b

NS NS 0.001bc 0.009 0.046d

NS 0.02c

NS

NS 0.028b 0.002b 0.012c

0.002b ⬍0.001c ⬍0.001b ⬍0.001b

For evaluation of renal calcifications and kidney size, patients with PKD were excluded (n ⫽ 51). PKD, polycystic kidney disease. b Patients with ACKD compared to controls. c Patients with ACKD and complex cysts compared to controls. d Patients with ACKD-associated renal cell carcinoma compared to controls. a

plantation was significantly shorter in carcinoma patients with ACKD than in the others as was the time since the beginning of ESRD (dialysis and transplantation time together; Table 2).

Discussion This study shows that the prevalence of patients with renal cell carcinoma in native kidneys after renal transplantation is 5% (previously and newly diagnosed cases together). Furthermore, in patients with ACKD, the prevalence is 19%, and in patients with complex cysts, it is 54%. The simple suggestion from these data to patients and their nephrologists is to perform an additional ultrasound of the native kidneys, an organ check that should be part of the regular posttransplantation patient

care at least once a year. Such an examination was followed by the new diagnosis of eight renal cell carcinomas (1.4% of the investigated patients) and the suspicion of three others, which could not be confirmed after nephrectomy. In addition, one renal cell carcinoma of the transplant was found. Because 25 of 27 previously and newly diagnosed renal cell carcinomas were associated with ACKD, this lesion seems to be the basal precondition. The prevalence of renal cell carcinoma in ESRD reported in the literature is 0.1 to 7%, with a mean value of 3.2 ⫾ 2.4% (n ⫽ 116,906) (5,14 –22). Noteworthy is that this prospective investigation shows a distinctly higher prevalence of renal cell carcinoma (5%) without mortality, compared with a retrospective and historical



5

Figure 2. Clear cell carcinoma (A) and papillary carcinoma (B) are present in one kidney (the contralateral kidney shows papillary carcinoma as well).

analysis of all patients from this department who received a transplant between 1968 and 1995. The prevalence of renal cell carcinoma in the retrospective evaluation was 0.5%, and the mortality was 33% (19). This comparison shows that the awareness of the development of renal cell carcinoma of the native kidneys has increased since then and that the tumors are detected at an earlier stage nowadays and therefore have a better prognosis. Nonetheless, the posttransplantation prophylactic patient care in this direction is still not adequate, because in a cross-sectional sonographic check that was done by nephrologists (mostly nonspecialized in ultrasound), additional carcinomas were found in 1.5% of the patients. One cause for the frequent diagnosis of renal cell carcinoma in our investigation may be related to the fact that the willingness to perform a CT scan in suspicious ultrasound cases was pronounced during the study. It would be interesting to know whether these 12 patients with newly suspected renal cell carcinomas (nine confirmed and three not confirmed by nephrectomy) had not had their yearly ultrasound check for more than 1 yr; however, a realistic answer from their nephrologists cannot be expected. Therefore, the question remains how often and which patients should be checked. One report in the literature showed in a follow-up study of moderately complex cystic lesions of the kidney (Bosniak category IIF) that two (5%) of 42 patients had developed renal cell carcinoma after 2 to 18 yr (median 5 yr) (23). These were patients without renal insufficiency. That means that in ACKD, we have to suggest a much higher rate of carcinoma development, a theory that can be derived from the high prevalence of renal cell carcinoma in ACKD (19.4%) and from the often observed bilateral carcinoma in ACKD (26% of carcinomas). Table 1 gives a proposal, according to our experience, of how to handle the routine ultrasound and/or CT or magnetic resonance imaging screening in renal transplant patients. The crucial question is whether cystic lesions of the Bosniak category IIF should be screened or, considering their

high rate of malignant changes (54% in our study), they should be treated by early nephrectomy (Table 1). All carcinomas were clinically inapparent. In all 34 carcinomas of 27 patients (19 preexistent and eight newly diagnosed), we found no lymph node involvement and only one lung metastasis. This benign course may be related to the fact that the tumors were small in these well-observed patients with frequent sonographic checks. The tumor classification was pT1 and pT2 in 85% of carcinomas, and the tumor grading was G1 and G2 in all cases. This finding confirms data that proliferative activity in ACKD-associated renal cell carcinomas is lower than in the sporadic type (24) and that prognosis is better, at least when diagnosed early, than in the sporadic type with 30 to 50% metastasis at diagnosis of the tumor (8). An evident difference of ACKD associated with sporadic renal cell carcinoma is the much more frequent papillary type in histology, 42% in our series and 10 to 15% in the sporadic type; the clear cell type to the contrary occurred in 58% of cases in our series compared with 70% in the sporadic type (25–27). We did not find any chromophobe renal cell carcinomas in our series. Renal cell carcinoma was frequently bilateral (27% compared with 1% in the sporadic carcinoma) and multifocal, as it is known from the literature (17,27–29). In one patient, we found a bilateral papillary carcinoma together with clear cell carcinoma at one side and renal adenoma at the other (Figure 2). Renal cell carcinoma was strongly associated with ACKD (19% in patients with ACKD and 0.5% in patients without). This finding means that ACKD seems to be a precondition for the development of renal cell carcinoma. The definition of ACKD is arbitrary. The threshold of cystic changes has not been agreed on and is different in pathologic and radiologic reports (from one to five cysts per kidney, up to 25 to 40% cystic changes of renal tissue [2,5,7,8,15,18,20,21]). The prevalence of ACKD in patients with end-stage renal failure thus varies between 30 and 90% according to the definition of ACKD, the time the patients

6



were on dialysis, and the kind of investigation (autopsy, ultrasound, CT, or clinical studies) (2,3,5,12,14,15,20,22,28,30,31). ACKD in our series was associated with older age, male gender, less often diabetes, and more often cardiac diseases (Table 2). An older age and more often male gender is known from the literature (1,12,15,18,20,22,27,29). The reported association of ACKD with nephrosclerosis (2,27) may be the result of the old age and frequent cardiac diseases of these patients. Surprising, ACKD in our series was not associated with a longer time on dialysis, as has been reported in the literature (1,2,5,12,18,22). Perhaps regression of cysts after renal transplantation may confound this widely known parameter (29,32,33). On the contrary, renal cell carcinoma was even associated with a shorter time of ESRD (Table 2). This state of affairs is probably because suspicious lesions of renal cell carcinoma are operated on as soon as suspected. Considering that renal cell carcinoma was found in 54% of patients with complicated cysts and that the two lesions are not always easy to distinguish, nephrectomy of kidneys with any diagnosed moderately complex cystic lesion (Bosniak category IIF) could be the consequence. The prevalence of ACKD and the behavior of cyst development after renal transplantation are not well studied. However, the better the renal function, the slower the development. This finding may explain the lower prevalence of ACKD in our series (23%) and that of others after renal transplantation (25%) (18) compared with earlier reports. In dialysis patients, the prevalence of ACKD is said to be 30 to 90% (2,3,5,12,14,15,20,22,28,30,31). Such an incidence would mean that renal transplantation is an indirect prevention of renal cell carcinoma. In this context, we admit that we do not know very much about the influence of immunosuppression on cyst formation. For example, recently, sirolimus was found to have a slowing and even regressing influence on renal cystogenesis in PKD (34 –36). Cyst formation in ACKD may be influenced by immunosuppression as well, and it argues for an influence of immunosuppression on cystogenesis that the renal transplant, nearly always exposed to renal insufficiency from the beginning after transplantation and often remaining in place even after transplant failure, almost never develops ACKD, at least according to our experience. The sporadic renal cell carcinoma mostly represents the clear cell type and is often associated with the genetic aberration of gene sequences in the short arm of chromosome 3 (3p) and of the von Hippel-Lindau tumor suppressor gene (26,37,38), whereas the papillary type of the renal cell carcinoma is characterized by the absence of 3p deletions and by trisomy and tetrasomy of chromosome 7 (⫹7) and trisomy of chromosome 17 (⫹17) (37). However, the development of renal cell carcinoma in ACKD is overrepresented by the papillary type (25,39,40). Chromosomal alterations that are seen in renal cell carcinoma with ACKD are both similar to and different from those that are seen in the sporadic tumors (38 – 41). The different genetic background of ACKD-associated renal cell carcinoma may explain the high prevalence and more benign course of this kind of tumor compared with the sporadic type.

Disclosures None.

References 1. Ishikawa I, Saito Y, Nakamura M, Takada K, Ishii H, Nakazawa T, Fukuda Y, Asaka M, Tomosugi N, Yuri T: Fifteen-year follow-up of acquired renal cystic disease: A gender difference. Nephron 75: 315–320, 1997 2. Matson MA, Cohen EP: Acquired cystic kidney disease: Occurrence, prevalence, and renal cancers. Medicine (Baltimore) 69: 217–226, 1990 3. Segerer S, Meister P: Acquired, cystic kidney disease in chronic dialysis patients: A retrospective study of 125 autopsies. 1: Cysts [in German]. Pathologe 19: 292–298, 1998 4. Al-Said J, Brumback MA, Moghazi S, Baumgarten DA, O’Neill WC: Reduced renal function in patients with simple renal cysts. Kidney Int 65: 2303–2308, 2004 5. Levine E, Slusher SL, Grantham JJ, Wetzel LH: Natural history of acquired renal cystic disease in dialysis patients: A prospective longitudinal CT study. AJR Am J Roentgenol 156: 501–506, 1991 6. Liu JS, Ishikawa I, Horiguchi T: Incidence of acquired renal cysts in biopsy specimens. Nephron 84: 142–147, 2000 7. Truong LD, Choi YJ, Shen SS, Ayala G, Amato R, Krishnan B: Renal cystic neoplasms and renal neoplasms associated with cystic renal diseases: Pathogenetic and molecular links. Adv Anat Pathol 10: 135–159, 2003 8. Hughson MD, Buchwald D, Fox M: Renal neoplasia and acquired cystic kidney disease in patients receiving longterm dialysis. Arch Pathol Lab Med 110: 592– 601, 1986 9. Cheuk W, Lo ES, Chan AK, Chan JK: Atypical epithelial proliferations in acquired renal cystic disease harbor cytogenetic aberrations. Hum Pathol 33: 761–765, 2002 10. Bosniak MA: The current radiological approach to renal cysts. Radiology 158: 1–10, 1986 11. Israel GM, Bosniak MA: An update of the Bosniak renal cyst classification system. Urology 66: 484 – 488, 2005 12. Narasimhan N, Golper TA, Wolfson M, Rahatzad M, Bennett WM: Clinical characteristics and diagnostic considerations in acquired renal cystic disease. Kidney Int 30: 748 – 752, 1986 13. Hartman DS, Aronson S, Frazer H: Current status of imaging indeterminate renal masses. Radiol Clin North Am 29: 475– 496, 1991 14. Grantham JJ, Levine E: Acquired cystic disease: Replacing one kidney disease with another. Kidney Int 28: 99 –105, 1985 15. Miller LR, Soffer O, Nassar VH, Kutner MH: Acquired renal cystic disease in end-stage renal disease: An autopsy study of 155 cases. Am J Nephrol 9: 322–328, 1989 16. Noronha IL, Ritz E, Waldherr R, Stein G, Fassbinder W: Renal cell carcinoma in dialysis patients with acquired renal cysts. Nephrol Dial Transplant 4: 763–769, 1989 17. Terasawa Y, Suzuki Y, Morita M, Kato M, Suzuki K, Sekino H: Ultrasonic diagnosis of renal cell carcinoma in hemodialysis patients. J Urol 152: 846 – 851, 1994 18. Heinz-Peer G, Schoder M, Rand T, Mayer G, Mostbeck GH: Prevalence of acquired cystic kidney disease and tumors in native kidneys of renal transplant recipients: A prospective US study. Radiology 195: 667– 671, 1995 19. Kliem V, Kolditz M, Behrend M, Ehlerding G, Pichlmayr R,


20.

21.

22.

23.

24.

25.

26.

27.

28.

29.

30.

Koch KM, Brunkhorst R: Risk of renal cell carcinoma after kidney transplantation. Clin Transplant 11: 255–258, 1997 Gulanikar AC, Daily PP, Kilambi NK, Hamrick-Turner JE, Butkus DE: Prospective pretransplant ultrasound screening in 206 patients for acquired renal cysts and renal cell carcinoma. Transplantation 66: 1669 –1672, 1998 Segerer S, Meister P: Acquired cystic kidney disease in patients on long-term dialysis: A retrospective study of 125 autopsies. Part 2: Tumors [in German]. Pathologe 19: 368 – 372, 1998 Denton MD, Magee CC, Ovuworie C, Mauiyyedi S, Pascual M, Colvin RB, Cosimi AB, Tolkoff-Rubin N: Prevalence of renal cell carcinoma in patients with ESRD pretransplantation: A pathologic analysis. Kidney Int 61: 2201– 2209, 2002 Israel GM, Bosniak MA: Follow-up CT of moderately complex cystic lesions of the kidney (Bosniak category IIF). AJR Am J Roentgenol 181: 627– 633, 2003 Ikeda R, Tanaka T, Moriyama MT, Kawamura K, Miyazawa K, Suzuki K: Proliferative activity of renal cell carcinoma associated with acquired cystic disease of the kidney: Comparison with typical renal cell carcinoma. Hum Pathol 33: 230 –235, 2002 Ishikawa I, Kovacs G: High incidence of papillary renal cell tumours in patients on chronic haemodialysis. Histopathology 22: 135–139, 1993 Hughson MD, Schmidt L, Zbar B, Daugherty S, Meloni AM, Silva FG, Sandberg AA: Renal cell carcinoma of endstage renal disease: A histopathologic and molecular genetic study. J Am Soc Nephrol 7: 2461–2468, 1996 Peces R, Martinez-Ara J, Miguel JL, Arrieta J, Costero O, Gorriz JL, Picazo ML, Fresno M: Renal cell carcinoma co-existent with other renal disease: Clinico-pathological features in pre-dialysis patients and those receiving dialysis or renal transplantation. Nephrol Dial Transplant 19: 2789 –2796, 2004 Dunnill MS, Millard PR, Oliver D: Acquired cystic disease of the kidneys: A hazard of long-term intermittent maintenance haemodialysis. J Clin Pathol 30: 868 – 877, 1977 Truong LD, Krishnan B, Cao JT, Barrios R, Suki WN: Renal neoplasm in acquired cystic kidney disease. Am J Kidney Dis 26: 1–12, 1995 Jabour BA, Ralls PW, Tang WW, Boswell WD Jr, Colletti PM, Feinstein EI, Massry SG: Acquired cystic disease of the kidneys. Computed tomography and ultrasonography appraisal in patients on peritoneal and hemodialysis. Invest Radiol 22: 728 –732, 1987


7

31. Almirall J, Ramon Ayuso J, Ponz E, Bru C, Revert L: Acquired cystic disease and renal cell carcinoma. Nephron 59: 165, 1991 32. Ishikawa I, Yuri T, Kitada H, Shinoda A: Regression of acquired cystic disease of the kidney after successful renal transplantation. Am J Nephrol 3: 310 –314, 1983 33. Lien YH, Hunt KR, Siskind MS, Zukoski C: Association of cyclosporin A with acquired cystic kidney disease of the native kidneys in renal transplant recipients. Kidney Int 44: 613– 616, 1993 34. Tao Y, Kim J, Schrier RW, Edelstein CL: Rapamycin markedly slows disease progression in a rat model of polycystic kidney disease. J Am Soc Nephrol 16: 46 –51, 2005 35. Shillingford JM, Murcia NS, Larson CH, Low SH, Hedgepeth R, Brown N, Flask CA, Novick AC, Goldfarb DA, Kramer-Zucker A, Walz G, Piontek KB, Germino GG, Weimbs T: The mTOR pathway is regulated by polycystin-1, and its inhibition reverses renal cystogenesis in polycystic kidney disease. Proc Natl Acad Sci U S A 103: 5466 – 5471, 2006 36. Walz G: Therapeutic approaches in autosomal dominant polycystic kidney disease (ADPKD): Is there light at the end of the tunnel? Nephrol Dial Transplant 21: 1752–1757, 2006 37. Kovacs G: Molecular cytogenetics of renal cell tumors. Adv Cancer Res 62: 89 –124, 1993 38. Yoshida M, Yao M, Ishikawa I, Kishida T, Nagashima Y, Kondo K, Nakaigawa N, Hosaka M: Somatic von HippelLindau disease gene mutation in clear-cell renal carcinomas associated with end-stage renal disease/acquired cystic disease of the kidney. Genes Chromosomes Cancer 35: 359 –364, 2002 39. Kovacs G: High frequency of papillary renal-cell tumours in end-stage kidneys: Is there a molecular genetic explanation? Nephrol Dial Transplant 10: 593–596, 1995 40. Hughson MD, Bigler S, Dickman K, Kovacs G: Renal cell carcinoma of end-stage renal disease: An analysis of chromosome 3, 7, and 17 abnormalities by microsatellite amplification. Mod Pathol 12: 301–309, 1999 41. Gronwald J, Baur AS, Holtgreve-Grez H, Jauch A, Mosimann F, Jichlinski P, Wauters JP, Cremer T, Guillou L: Chromosomal abnormalities in renal cell neoplasms associated with acquired renal cystic disease. A series studied by comparative genomic hybridization and fluorescence in situ hybridization. J Pathol 187: 308 –312, 1999

RENAL CELL CARCINOMA IN TRANSPLANT RECIPIENTS WITH ACQUIRED CYSTIC

Recommend Documents